Your browser doesn't support javascript.
loading
Current progress of nanomedicine for prostate cancer diagnosis and treatment.
Zhao, Jiang; Zhang, Chi; Wang, Weihao; Li, Chen; Mu, Xupeng; Hu, Kebang.
Afiliação
  • Zhao J; Department of Urology, The First Hospital of Jilin University, Changchun 130021, China.
  • Zhang C; Department of Urology, The First Hospital of Jilin University, Changchun 130021, China.
  • Wang W; Department of Plastic and Reconstructive Surgery, The First Hospital of Jilin University, Changchun 130021, China.
  • Li C; Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun 130021, China.
  • Mu X; Scientific Research Center, China-Japan Union Hospital, Jilin University, Changchun 130033, China. Electronic address: muxupeng@jlu.edu.cn.
  • Hu K; Department of Urology, The First Hospital of Jilin University, Changchun 130021, China. Electronic address: hukb@jlu.edu.cn.
Biomed Pharmacother ; 155: 113714, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36150309
Prostate cancer (PCa) is the most common new cancer case and the second most fatal malignancy in men. Surgery, endocrine therapy, radiotherapy and chemotherapy are the main clinical treatment options for PCa. However, most prostate cancers can develop into castration-resistant prostate cancer (CRPC), and due to the invasiveness of prostate cancer cells, they become resistant to different treatments and activate tumor-promoting signaling pathways, thereby inducing chemoresistance, radioresistance, ADT resistance, and immune resistance. Nanotechnology, which can combine treatment with diagnostic imaging tools, is emerging as a promising treatment modality in prostate cancer therapy. Nanoparticles can not only promote their accumulation at the pathological site through passive targeting techniques for enhanced permeability and retention (EPR), but also provide additional advantages for active targeting using different ligands. This property results in a reduced drug dose to achieve the desired effect, a longer duration of action within the tumor and fewer side effects on healthy tissues. In addition, nanotechnology can create good synergy with radiotherapy, chemotherapy, thermotherapy, photodynamic therapy and gene therapy to enhance their therapeutic effects with greater scope, and reduce the resistance of prostate cancer. In this article, we intend to review and discuss the latest technologies regarding the use of nanomaterials as therapeutic and diagnostic tools for prostate cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China